Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Study Identifier:
ALXN2030-HV-101
ClinicalTrials.gov Identifier:
NCT05501717
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2030
  • Drug: Placebo
Date
Aug 2022 - Oct 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years
Requirements Information
Sex
Female & Male
Age
18 - 60 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2030
  • Drug: Placebo
Date
Aug 2022 - Oct 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years years
Requirements Information

Protocol Summary

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Harrow, United Kingdom, HA1 3UJ
Status
Recruiting
Location
Research Site
Harrow, United Kingdom, HA1 3UJ
Status
Recruiting